Free Trial
NASDAQ:MTVA

MetaVia (MTVA) Stock Price, News & Analysis

MetaVia logo
$0.79 -0.02 (-2.48%)
As of 05/23/2025 04:00 PM Eastern

About MetaVia Stock (NASDAQ:MTVA)

Key Stats

Today's Range
$0.73
$0.83
50-Day Range
$0.65
$1.84
52-Week Range
$0.65
$5.30
Volume
330,186 shs
Average Volume
437,277 shs
Market Capitalization
$6.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

MetaVia Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

MTVA MarketRank™: 

MetaVia scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MetaVia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MetaVia has only been the subject of 2 research reports in the past 90 days.

  • Read more about MetaVia's stock forecast and price target.
  • Earnings Growth

    Earnings for MetaVia are expected to grow in the coming year, from ($3.90) to ($1.64) per share.

  • Price to Book Value per Share Ratio

    MetaVia has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for MTVA.
  • Dividend Yield

    MetaVia does not currently pay a dividend.

  • Dividend Growth

    MetaVia does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MTVA.
  • News Sentiment

    MetaVia has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for MetaVia this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for MTVA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MetaVia insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.05% of the stock of MetaVia is held by insiders.

  • Percentage Held by Institutions

    Only 1.37% of the stock of MetaVia is held by institutions.

  • Read more about MetaVia's insider trading history.
Receive MTVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter.

MTVA Stock News Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Maxim Group Lowers MetaVia (NASDAQ:MTVA) Price Target to $3.00
See More Headlines

MTVA Stock Analysis - Frequently Asked Questions

MetaVia's stock was trading at $2.03 at the start of the year. Since then, MTVA shares have decreased by 61.1% and is now trading at $0.7898.
View the best growth stocks for 2025 here
.

MetaVia Inc. (NASDAQ:MTVA) issued its earnings results on Wednesday, May, 14th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.21.

Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
5/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MTVA
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$12.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+849.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.44 per share
Price / Book
0.23

Miscellaneous

Free Float
8,526,000
Market Cap
$6.84 million
Optionable
N/A
Beta
0.21
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:MTVA) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners